ReviewBiosensors2026
Recent Progress in Artificial Intelligence in Biosensor Development: From Bioprobe Design to Fabrication and Signal Analysis.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The coronavirus disease 2019 (COVID-19) pandemic highlighted the need for rapid, accurate, and point-of-care diagnostic technologies, accelerating interest in biosensors as next-generation analytical platforms. However, biosensor performance is governed by a connected sequence of processes, including bioprobe-target recognition, sensor fabrication, structural optimization, and signal interpretation. Because these processes involve multiple interacting variables, conventional empirical approaches often have limitations in efficiently optimizing biosensor performance and interpreting complex analytical signals. Artificial intelligence (AI) and machine learning (ML) provide tools to model these relationships and support prediction-guided biosensor development. This review discusses recent progress in AI-assisted biosensor development in three sequential stages. First, AI-assisted bioprobe design is reviewed, including in silico aptamer discovery, smart-SELEX-based aptamer screening, and peptide receptor design for improving molecular recognition. Second, AI-driven sensor fabrication and structural optimization are discussed, focusing on electrochemical feature extraction, paper-based microfluidic device optimization, and optical biosensor parameter prediction. Third, ML-based signal analysis is examined as a strategy for converting complex electrochemical, colorimetric, and optical responses into quantitative analytical outputs. By organizing these examples as a connected workflow rather than as separate applications, this review highlights how AI can link molecular design, device engineering, and signal interpretation to accelerate the development of next-generation biosensors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.